ReviewFrontiers in genetics2014
Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
Review in Frontiers in genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03791151 (Effect of Copper Transporter-1 Genetic Polymorphism on Platinum Based Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Copper Transporter-1 Genetic Polymorphism on Platinum Based Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients
Who cites it
15 citing papers in PubMed.
- Role of GSTM1 and GSTT1 Gene Polymorphisms on Lung Cancer Susceptibility and Effect on Platinum-Based Chemotherapy-Induced Toxicity in Bangladeshi Lung Cancer Patients.Journal of cancer epidemiology · 2024Article
- Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.Methods in molecular biology (Clifton, N.J.) · 2022Review
- Observational
- Nano drug delivery systems in upper gastrointestinal cancer therapy.Nano convergence · 2020Review
- Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches.Annals of translational medicine · 2020Review
- First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.Cancer management and research · 2020Review
- Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review.Pharmacogenomics and personalized medicine · 2020Review
- Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients.Frontiers in pharmacology · 2019Article
- Glutathione Transferases: Potential Targets to Overcome Chemoresistance in Solid Tumors.International journal of molecular sciences · 2018Review
- Association between genetic polymorphisms and platinum-induced ototoxicity in children.Oncotarget · 2018Article
- Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Clinical pharmacokinetics · 2017Review
- M3 Macrophages Stop Division of Tumor Cells In Vitro and Extend Survival of Mice with Ehrlich Ascites Carcinoma.Medical science monitor basic research · 2017Article
- Genome-wide association study identifies four SNPs associated with response to platinum-based neoadjuvant chemotherapy for cervical cancer.Scientific reports · 2017Article
- Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites Carcinoma.Medical science monitor basic research · 2015Article
- Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic.Frontiers in genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several recent pharmacogenetic studies have investigated the variability in both outcome and toxicity in cisplatin-based therapies. These studies have focused on the genetic variability of therapeutic targets that could affect cisplatin response and toxicity in diverse type of cancer including lung, gastric, ovarian, testicular, and esophageal cancer. In this review, we seek to update the reader in this area of investigation, focusing primarily on DNA reparation enzymes and cisplatin metabolism through Glutathione S-Transferases (GSTs). Current evidence indicates a potential application of pharmacogenetics in therapeutic schemes in which cisplatin is the cornerstone of these treatments. Therefore, a collaborative effort is required to study these molecular characteristics in order to generate a genetic panel with clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.